OOIR: Observatory of International Research

Papers

(The median citation count of Seminars in Hematology is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)

Article	Citations
CAR T-cell therapy comes of age: Introductory editorial for the special issue	62
Special issue on chronic lymphocytic leukemia: Prognostication and therapeutic options introductory editorial	58
Extramedullary myeloma in the era of CAR T-cell and bispecific antibody therapies	52
Clonality in immune aplastic anemia: Mechanisms of immune escape or malignant transformation	50
Clonal hematopoiesis and VEXAS syndrome: survival of the fittest clones?	46
Clinical applications of circulating tumor DNA in Hodgkin lymphoma	44
The winding road: Infectious disease considerations for CAR-T and other novel adoptive cellular therapies in the era of COVID-19	43
How to set up a clinical research center in Brazil, as an example of a middle-income country	41
Epidemiology and etiology of diffuse large B-cell lymphoma	39
TET2 mutation as prototypic clonal hematopoiesis lesion	37
Somatic mutations in “benign” blood diseases	37
The future of lymphoma diagnosis, prognosis, and treatment monitoring in countries with limited access to pathology services	34
Antibody and immunotherapy in diffuse large B-cell lymphoma	30
Lessons learned from the Eµ-TCL1 mouse model of CLL	27
Immune-driven clonal cell selection at the intersection among cancer, infections, autoimmunity and senescence	26
The role of viruses in HIV-associated lymphomas	24
Vaccinations in patients with chronic lymphocytic leukemia	22
Intestinal microbiome and myelodysplastic syndromes: Current state of knowledge and perspectives for future	21
The molecular map of CLL and Richter's syndrome	19
Report of Consensus Panel 5 from the 12th International Workshop on Waldenström’s Macroglobulinemia on the management of patients with intolerance or resistance to covalent BTK inhibitors	17
Accelerating accessibility of CAR-T/NK therapies – Are AlloCARs and rapid manufacturing platforms the road ahead in improving access in multiple myeloma?	17
outside front cover, PMS 8883 metallic AND 4/C	16
outside front cover, PMS 8883 metallic AND 4/C	16
Tribute to an editor: Neal S. Young As a Medical Editor and Writer	15
Clonal hematopoiesis	15

At the cusp of a cure in Myeloma: Insights into pathogenesis, modeling and therapeutics	14
Cellular and immunotherapies for myelodysplastic syndromes	13
B-cell receptor immunoglobulin stereotypy in chronic lymphocytic leukemia: Key to understanding disease biology and stratifying patients	13
outside front cover, PMS 8883 metallic AND 4/C	13
Management of Myelodysplastic Syndrome in Pregnant Patients: Treatment Approaches and Considerations	12
Advancements in bispecific antibodies for multiple myeloma: What's new and what lies ahead	11
Report of Consensus Panel 3 from the 11th International workshop on Waldenström's Macroglobulinemia: Recommendations for molecular diagnosis in Waldenström's Macroglobulinemia	11
Challenges and opportunities of CAR T-cell therapies for CLL	11
Aplastic anemia: Quo vadis?	10
Mendelian inheritance of anemia due to disturbed iron homeostasis	10
Access to essential therapy for sickle cell disease in Africa: Experience from a national program in Ghana	9
The biology of classical Hodgkin lymphoma	9
The psychiatric and psychological sequelae of vaccine-induced immune thrombotic thrombocytopenia (VITT)	9
Mobilizing CARs: Benefits, drawbacks, and directions for outpatient CAR T-cell therapy	9
A tower of babel of acronyms? The shadowlands of MGUS/MBL/CHIP/TCUS	8
VEXAS within the spectrum of rheumatologic disease	8
The pediatric approach to Hodgkin lymphoma	8
Genetics of somatic auto-inflammatory disorders	7
Report of consensus panel 2 from the 12th international workshop on the management of Bing-Neel syndrome in patients with Waldenstrom’s Macroglobulinemia	7
Somatic compensation of inherited bone marrow failure	7
Somatic mutations in acquired pure red cell aplasia	7
Iron and erythropoiesis: A mutual alliance	7
Understanding MDS stem cells: Advances and limitations	7
The crossroads of cancer therapies and clonal hematopoiesis	6
20 years of Hepcidin: How far we have come	6
The spectrum of somatic mutations in large granular lymphocyte leukemia, rheumatoid arthritis, and Felty's syndrome	6
Clinical applications of circulating tumor DNA in central nervous system lymphoma	6
DLBCL arising from indolent lymphomas: How are they different?	6
Modernizing multiple myeloma clinical trial eligibility to improve equity and inclusivity by hematological parameters	5
Infectious complications of chimeric antigen receptor (CAR) T-cell therapies	5
Forging international collaboration and alliances to establish the largest transplant center in the north of Vietnam	5
Current challenges and new approaches to implementing optimal management of sickle cell disease in sub-Saharan Africa	5
outside front cover, PMS 8883 metallic AND 4/C	5
outside front cover, PMS 8883 metallic AND 4/C	5
miRNA Biology in Chronic Lymphocytic Leukemia	5
License for a CAR T: Examining patient eligibility	5
Report of consensus Panel 4 from the 11th International Workshop on Waldenstrom's macroglobulinemia on diagnostic and response criteria	5
Report of consensus panel 7 from the 11th international workshop on Waldenström macroglobulinemia on priorities for novel clinical trials	5
Measurable residual disease after CAR T-cell therapy	5
Report of Consensus Panel 3 from the 12th International Workshop on Waldenström’s Macroglobulinemia on the management of patients with high-risk disease	5
Clonal hematopoiesis in the setting of hematopoietic cell transplantation	5
Report of consensus panel 1 from the 11th International Workshop on Waldenstrom's Macroglobulinemia on management of symptomatic, treatment-naïve patients	5
Updates on the biology of chronic lymphocytic leukemia: introductory editorial	4
Platelet-activating anti-PF4 disorders: An overview	4
Special edition of the Seminars in Hematology series on Global Hematology Care	4
Highlights of the 11th International Workshop on Waldenstrom's Macroglobulinemia: What we learned, and how it will impact scientific discovery and patient care	4
Collaborations, colleagues, and friendships: The Hematology Branch and blood disease centers in Asia	4
Shaping the bone through iron and iron-related proteins	4
Inflammation in myelodysplastic syndrome pathogenesis	4
RNA splicing as a therapeutic target in myelodysplastic syndromes	4

Hemolytic paroxysmal nocturnal hemoglobinuria: 20 years of medical progress	4
Report of consensus panel 2 from the 11th international workshop on Waldenström's macroglobulinemia on the management of relapsed or refractory WM patients	4
The role of autologous stem-cell transplantation in classical Hodgkin lymphoma in the modern era	4
outside front cover, PMS 8883 metallic AND 4/C	4
outside front cover, PMS 8883 metallic AND 4/C	4
Toward a pathophysiology inspired treatment of VEXAS syndrome	3
Applications of virus-specific T cell therapies post-BMT	3
Melanoma antigen genes (MAGE); novel functional targets in multiple myeloma	3
Infections and antimicrobial prophylaxis in patients with myelodysplastic syndromes	3
Tuning CAR T-cell therapies for efficacy and reduced toxicity	3
The case for prioritizing malignant hematology services in low- and middle-income countries	3
Special issue on circulating tumor DNA: Introductory editorial	3
Characteristic bone marrow findings in patients with UBA1 somatic mutations and VEXAS syndrome	3
masthead	3
Inequalities in access to treatment in Argentina: Differences in management of CLL and multiple myeloma?	3
Role of the tumor microenvironment in CLL pathogenesis	3
The Management of older patients with Hodgkin lymphoma: implications of S1826	3
The Road More or Less Traveled- Examining the Role of Consolidative Allogeneic Hematopoietic Stem Cell Transplantation After Chimeric Antigen Receptor T Cell Therapy in B-cell ALL	3
Gene editing for sickle cell disease and transfusion dependent thalassemias- A cure within reach	2
Immunosuppressive therapy in severe aplastic anemia	2
Beyond HMAs: Novel Targets and Therapeutic Approaches	2
Cell-free DNA in large B-cell lymphoma: MRD and beyond	2
Biological, prognostic, and therapeutic impact of the epigenome in CLL	2
outside front cover, PMS 8883 metallic AND 4/C	2
Patient-reported outcomes in early phase trials for patients with myelodysplastic syndromes	2
Pathogenesis of vaccine-induced immune thrombotic thrombocytopenia (VITT)	2
Smoldering multiple myeloma: Integrating biology and risk into management	2
outside front cover, PMS 8883 metallic AND 4/C	2
Longitudinal Aspects of VITT	2
Hepatitis C virus-associated B-cell lymphomas: The importance of the new direct antiviral agent therapy	2
Immunocompetent mouse models of multiple myeloma	2
Palliative care needs of patients with hematologic malignancies and family caregivers and challenges of palliative care provision in Asia: A review of evidence	2
outside front cover, PMS 8883 metallic AND 4/C	2
The natural killer cell immunotherapy platform: An overview of the landscape of clinical trials in liquid and solid tumors	2
Beyond SARS-CoV2, the role of viruses in the pathogenesis of hematologic malignancies	2
Introduction to series: Diffuse large B-cell lymphoma	2
Clinical manifestations of clonal hematopoiesis: What has SF3B1-mutant MDS taught us?	2
Clinical picture of VITT	2
Mouse models of CLL: In vivo modeling of disease initiation, progression, and transformation	2